Flow Pharma is dedicated to immunotherapy innovation.
Our exclusive technology and manufacturing expertise are poised to transform the treatment and prevention of cancer and viral disease.
Flovid-20
Flovid-20
An inhaled treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations..
FlowVax Ebola & Marburg
Ebola, Marburg
Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target this virus, long-lasting infection prevention is attainable.
FlowVax BreastCA
Cancer
A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.
FlowVax HPV
Cancer, HPV
A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.
News & Press
Delta and Omicron Variants are Driving New Cases
Uncategorized
During the COVID-19 pandemic, new cases in the U.S. have repeatedly risen and dropped dramatically.
More Evidence for T-Cells: Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts
COVID-19
A new research paper led by the Imperial College London, published in the peer-reviewed journal nature communications, finds the following:.
The Peer Reviewed Journal Vaccines Published the Results of Flow Pharma’s COVID-19 Primate Study
Company Update, COVID-19, FLOVID-20
Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing the FlowVax™ peptide vaccine platform technology, today announced the publication of an article describing research performed at the University of Texas Medical Branch at Galveston (UTMB)
Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies
Research Publications
In December 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of pneumonia with severe respiratory distress and outbreaks in Wuhan, China.
